Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | CRHBP | P24387 | 1/20 | 0.81 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | DHFR | P00374 | 6/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17220216 | 0.92 | MAPT (0.69) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL13363710 | 0.83 | MAPT (1.00) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL796138 | 0.83 | MAPT (0.59) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL796423 | 0.81 | MAPT (0.60) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL796039 | 0.81 | MAPT (0.72) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL6259153 | 0.80 | NPSR1 (0.74) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL796040 | 0.78 | MAPT (0.53) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL17220372 | 0.77 | MAPT (0.67) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL13752166 | 0.76 | MAPT (0.73) | MAPTCRHBPCRHR2NPSR1TSHR | |
| SCHEMBL8021954 | 0.74 | MAPT (0.49) | MAPTCRHBPCRHR2NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | MAPT 2602/4885CRHBP 1166/4885CRHR2 284/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | MAPT 2602/4885CRHBP 1166/4885CRHR2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.